Inventisbio Completes Patient Enrollment for Psoriasis Drug D-2570 Phase III Trial

Stock News03-26

Inventisbio Co.,Ltd. (688382.SH) announced that patient enrollment has been completed for the registrational Phase III clinical trial of its self-developed TYK2 inhibitor D-2570, intended for the treatment of moderate-to-severe plaque psoriasis. The company-developed D-2570 is a novel oral selective inhibitor targeting tyrosine kinase 2 (TYK2) and is designed to treat autoimmune diseases such as psoriasis. D-2570 works by selectively binding to the JH2 domain of the TYK2 pseudokinase, inhibiting TYK2 kinase activity, thereby blocking TYK2-dependent cytokine signaling-mediated phosphorylation of STAT proteins. This mechanism reduces the release of inflammatory factors and contributes to immune regulation.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1150325653?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-26 16:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1150325653","market":"sh","top_or_hot":-1,"title":"Inventisbio Completes Patient Enrollment for Psoriasis Drug D-2570 Phase III Trial","media":"Stock News","content":"<p>Inventisbio Co.,Ltd. (688382.SH) announced that patient enrollment has been completed for the registrational Phase III clinical trial of its self-developed TYK2 inhibitor D-2570, intended for the treatment of moderate-to-severe plaque psoriasis. The company-developed D-2570 is a novel oral selective inhibitor targeting tyrosine kinase 2 (TYK2) and is designed to treat autoimmune diseases such as psoriasis. D-2570 works by selectively binding to the JH2 domain of the TYK2 pseudokinase, inhibiting TYK2 kinase activity, thereby blocking TYK2-dependent cytokine signaling-mediated phosphorylation of STAT proteins. This mechanism reduces the release of inflammatory factors and contributes to immune regulation.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Inventisbio Completes Patient Enrollment for Psoriasis Drug D-2570 Phase III Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInventisbio Completes Patient Enrollment for Psoriasis Drug D-2570 Phase III Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-26 16:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Inventisbio Co.,Ltd. (688382.SH) announced that patient enrollment has been completed for the registrational Phase III clinical trial of its self-developed TYK2 inhibitor D-2570, intended for the treatment of moderate-to-severe plaque psoriasis. The company-developed D-2570 is a novel oral selective inhibitor targeting tyrosine kinase 2 (TYK2) and is designed to treat autoimmune diseases such as psoriasis. D-2570 works by selectively binding to the JH2 domain of the TYK2 pseudokinase, inhibiting TYK2 kinase activity, thereby blocking TYK2-dependent cytokine signaling-mediated phosphorylation of STAT proteins. This mechanism reduces the release of inflammatory factors and contributes to immune regulation.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"III","symbol_name":"信息服务","start_time":0,"source_url":"","article_id":"1150325653","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1150325653","pubTimestamp":1774515449,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Inventisbio Co.,Ltd. (688382.SH) announced that patient enrollment has been completed for the registrational Phase III clinical trial of its self-developed TYK2 inhibitor D-2570, intended for the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688382":"益方生物","III":"信息服务","BK0239":"医药制造","BK4134":"信息科技咨询与其它服务"},"translate_title":"Inventisbio完成银屑病药物D-2570 III期试验患者入组","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688382":1,"III":1},"content_text":"Inventisbio Co.,Ltd. (688382.SH) announced that patient enrollment has been completed for the registrational Phase III clinical trial of its self-developed TYK2 inhibitor D-2570, intended for the treatment of moderate-to-severe plaque psoriasis. The company-developed D-2570 is a novel oral selective inhibitor targeting tyrosine kinase 2 (TYK2) and is designed to treat autoimmune diseases such as psoriasis. D-2570 works by selectively binding to the JH2 domain of the TYK2 pseudokinase, inhibiting TYK2 kinase activity, thereby blocking TYK2-dependent cytokine signaling-mediated phosphorylation of STAT proteins. This mechanism reduces the release of inflammatory factors and contributes to immune regulation.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1150325653","isCrawlerRequest":true}